



## INOVIQ AWARDED ADDITIONAL BTB FUNDING TO DEVELOP SUBB2M-BASED TESTS

- INOVIQ awarded additional funding from Biomedical Translation Bridge (BTB) program, taking total grant to \$461,985
- New project to develop proprietary monoclonal antibodies for use in SubB2M immunoassays for cancer detection
- Service agreement signed with Monash Antibody Technologies Facility

**Melbourne, Australia, 10 January 2022:** INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that it has been awarded additional funding of \$89,331 from MTPConnect's Biomedical Translation Bridge (BTB) program. This funding is in addition to an earlier \$372,654 grant awarded in September 2020 under the BTB program, and will be directed toward a project to develop proprietary monoclonal antibodies for use in SubB2M immunoassays for cancer detection.

INOVIQ plans to develop up to six monoclonal antibodies for use in its SubB2M immunoassays for breast, ovarian and other cancers. SubB2M detects a cancer biomarker, Neu5Gc, that has been implicated in breast, ovarian, prostate, colon, melanoma and other cancers. The use of SubB2M in combination with tissue-specific cancer biomarkers is expected to improve the accuracy of existing cancer biomarker tests, such as the CA15.3 test for monitoring breast cancer and the CA125 test for monitoring ovarian cancer, by reducing false positives.

The BTB funding will cover antigen purchase and monoclonal antibody production and the project is expected to be completed by June 2022. Under the project, INOVIQ has signed a service agreement with Monash Antibody Technologies Facility for custom monoclonal antibody development.

CEO Dr Leeearne Hinch said: "INOVIQ is pleased to have received this additional BTB funding to develop proprietary monoclonal antibodies. These antibodies are a key reagent used in our SubB2M-based tests and their development will secure supply of fit-for-purpose antibodies for commercialisation of our SubB2M tests for breast and ovarian cancers."

CSO Dr Gregory Rice said: "Securing the supply of key monoclonal antibodies to pair with our unique SubB2M cancer probe will significantly advance the development of INOVIQ's SubB2M-based tests. The proprietary monoclonal antibodies will be integrated into the current SubB2M tests for breast and ovarian cancers. We also plan to evaluate the custom antibodies for inclusion in the Company's molecular NET technology and EXO-NET<sup>®</sup> product range to develop exosome-based diagnostics."

Delivered by MTPConnect, the Australian Government's BTB program is a \$22.3 million Medical Research Future Fund (MRFF) initiative that provides up to \$1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept, turning innovative medical ideas into reality.

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS

**Dr Leeearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

**ABOUT INOVIQ LTD**

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

**ABOUT BIOMEDICAL TRANSLATION BRIDGE (BTB) PROGRAM**

The Biomedical Translation Bridge program is an initiative of the Australian Government's Medical Research Future Fund. The BTB program can provide up to A\$1 million of funding over a maximum 22-month period to help eligible organisations fund and nurture early-stage health and medical research to reach proof-of-concept with potential to attract further capital and support. The BTB program is operated by MTPConnect, in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.

**FORWARD LOOKING STATEMENTS**

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.